Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development. (Q48404127)

11 February 2018

title

Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development. (English)

1 reference

11 February 2018

author name string

Bryan L Roth

series ordinal

1

1 reference

11 February 2018

David A Shapiro

series ordinal

2

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 December 2001

1 reference

11 February 2018

Expert Opinion on Therapeutic Targets

published in

1 reference

11 February 2018

volume

5

1 reference

11 February 2018

page(s)

685-695

1 reference

11 February 2018

issue

6

1 reference

11 February 2018

5-HT receptor classification and nomenclature: towards a harmonization with the human genome

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Treatment of neuropathic pain with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Buspirone: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Obesity drugs and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Multiple serotonin receptors: clinical and experimental aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Selections from current literature: pharmacological treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Crystal structure of rhodopsin: A G protein-coupled receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: the third intracellular loop is alpha-helical and binds purified arrestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Seroquel: biochemical profile of a potential atypical antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Does olanzapine have antidepressant properties? A retrospective preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

25 years since the discovery of presynaptic receptors: present knowledge and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Down-regulation of serotonin2, but not of beta-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin2 and beta-adrenergic receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Hallucinogens, serotonin and obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

LSD treatment in a severe case of compulsive neurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Human leptin regulation and promise in pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

21 January 2018

Novel anti-obesity drugs

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Biological influences on obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Anorectic drugs and pulmonary hypertension from the bedside to the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Recent developments in the psychopharmacology of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.5.6.685

21 January 2018

Identifiers

DOI

10.1517/14728222.5.6.685

1 reference

11 February 2018

PubMed ID

12540278

1 reference

11 February 2018